Hoth Therapeutics (NASDAQ:HOTH) Posts Earnings Results, Misses Estimates By $0.06 EPS

Hoth Therapeutics (NASDAQ:HOTH) issued its quarterly earnings data on Friday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.06), FiscalAI reports.

Hoth Therapeutics Trading Down 4.0%

HOTH traded down $0.03 during midday trading on Friday, reaching $0.81. The company’s stock had a trading volume of 160,731 shares, compared to its average volume of 544,161. The company has a fifty day simple moving average of $0.98 and a 200 day simple moving average of $1.21. The stock has a market cap of $12.50 million, a P/E ratio of -0.76 and a beta of 0.50. Hoth Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.12.

Analyst Upgrades and Downgrades

HOTH has been the subject of a number of recent analyst reports. Wall Street Zen raised Hoth Therapeutics to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Hoth Therapeutics in a research note on Monday, December 22nd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price objective on shares of Hoth Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $5.00.

Institutional Investors Weigh In On Hoth Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of HOTH. Lido Advisors LLC acquired a new stake in shares of Hoth Therapeutics in the third quarter worth $32,000. Kestra Private Wealth Services LLC acquired a new position in Hoth Therapeutics during the 3rd quarter valued at $51,000. Geode Capital Management LLC boosted its holdings in Hoth Therapeutics by 8.0% in the 2nd quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after purchasing an additional 9,071 shares during the period. Virtu Financial LLC bought a new stake in Hoth Therapeutics in the 3rd quarter valued at $184,000. Finally, Citadel Advisors LLC acquired a new stake in Hoth Therapeutics in the 3rd quarter worth $232,000. Institutional investors and hedge funds own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.